Displaying drugs 11026 - 11050 of 12882 in total
Posoleucel
Investigational
Tabituximab barzuxetan yttrium Y-90
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
Yttrium Y-90 Labetuzumab
Investigational
Allogenic bone marrow-derived mesenchymal stem cells
Investigational
BHT-3034
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
NKX101
NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Investigational
PBKR03
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
TN-401
TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Investigational
ATX-01
ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
Investigational
Gentulizumab
Investigational
Zilganersen
Investigational
ION283
Investigational
LipidRescue
Investigational
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Ersodetug
Investigational
NBL-015
Investigational
AGuIX
AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates. It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.
Investigational
Canoctakin
Investigational
OM-301
Investigational
ACT-1 peptide
Investigational
FCX-013
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
INO-3107
Investigational
KB105
Investigational
MK-2225
Investigational
Displaying drugs 11026 - 11050 of 12882 in total